Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/xPvvRfY7rtc/226786.php
Sunday, May 29, 2011
ARCA Biopharma Announces Planned Expansion Of Gencaro Development To Atrial Fibrillation
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it is planning to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects more than 2.4 million patients in the United States...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment